A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II)

Trial Profile

A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II)

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2016

At a glance

  • Drugs Levetiracetam (Primary) ; Zonisamide (Primary) ; Lamotrigine; Valproic acid
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Acronyms SANAD-II
  • Most Recent Events

    • 13 Jul 2016 Status changed from recruiting to completed.
    • 04 Nov 2015 Accrual to date is 69% according to the United Kingdom Clinical Research Network record.
    • 04 Oct 2015 Accrual to date is 66% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top